Vir Biotechnology (VIR) Equity Average (2018 - 2026)

Vir Biotechnology has disclosed Equity Average across 9 years of filings, most recently posting $789.0 million for Q1 2026.

• Equity Average for Q1 2026 came in at $789.0 million, down 28.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $789.0 million (down 28.08% YoY), and the FY2025 annual result was $957.8 million, down 30.1% from the prior year.
• Equity Average came in at $789.0 million for Q1 2026 at Vir Biotechnology, up from $780.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $2.1 billion in Q4 2022 to a low of $780.7 million in Q4 2025.
• The 5-year median for Equity Average is $1.6 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Equity Average soared 184.74% in 2022 and slumped 34.81% in 2025, its largest moves.
• Vir Biotechnology's Equity Average stood at $2.1 billion in 2022, then retreated by 22.77% to $1.6 billion in 2023, then decreased by 26.77% to $1.2 billion in 2024, then slumped by 34.7% to $780.7 million in 2025, then increased by 1.07% to $789.0 million in 2026.
• The last three Equity Average figures came in at $789.0 million (Q1 2026), $780.7 million (Q4 2025), and $871.8 million (Q3 2025), per Business Quant data.